QUEBEC CITY, April 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.
Irene Seipelt, Ph.D., Associate Director, Drug Discovery & Preclinical Development at AEterna Zentaris, will make both presentations.
Copies of the abstracts are currently available and can be viewed on-line through the AACR 2010 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/abstracts.aspx.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
CONTACT: Investor Relations: Ginette Vallieres, Investor Relations
Coordinator, (418) 652-8525 ext. 265, gvallieres@aezsinc.com; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext.
406, pburroughs@aezsinc.com
